



Chronic Noninfectious Uveitis: From Pathophysiology to Management

Guest Editor:

Prof. Dr. Uwe Pleyer

Center of Ocular Inflammation,
Charité, Berlin, Germany

Deadline for manuscript
submissions:

closed (31 August 2023)

Message from the Guest Editor

Chronic noninfectious uveitis remains a leading cause of visual impairment and represents a significant burden of legal and economic blindness. Although the molecular/immunological mechanisms of noninfectious uveitis have been analysed, leading to new findings, many details of the chronic inflammatory processes remain unknown. Complex interactions are increasingly discovered in chronic intraocular inflammation. The relevance of immunosenescence and inflammaging is widely unknown, but they are thought to modulate disease evolution. This complex immune-biologic scenario is often highly destructive and remains a challenge for early and accurate diagnosis and effective management. Therefore, the development of improved diagnostic and therapeutic modalities, in particular OCT and immune modulatory agents, has received intense attention from the uveitis research community.

This Special Issue aims to provide expert insight into the current diagnostic and therapeutic procedures for chronic uveitis. In addition, current developments regarding biomarkers for monitoring chronic inflammation will be included. Both original papers and review articles will be considered.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)